Coupled with these observations in other malignancies and biological explanations for the role of RB in mediating immune response, the association of RB1 mutation with lack of response to immunotherapy should be evaluated in larger cohorts of NSCLC. Here, RB1 is linked to non-small cell lung carcinoma.